Novartis launches Arcapta Neohaler

EAST HANOVER, N.J. — Novartis has launched a new treatment for chronic obstructive pulmonary disease, the drug maker said Monday.



Novartis Pharmaceuticals, the U.S. division of the Swiss drug manufacturer, announced the launch of Arcapta Neohaler (indacaterol inhalation powder) in the 75-mcg strength. The Food and Drug Administration approved the drug last July.



The company said the inhaler is designed for the long-term maintenance bronchodilator treatment of airflow obstruction in adults with COPD, which includes the diseases chronic bronchitis and emphysema, though the drug is not approved by the FDA for treating asthma.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.